º» »ó´ãÀº °ø°³µÇ¹Ç·Î ºñ°ø°³»ó´ãÀ» ¿øÇϽøé [ÀüÈ­»ó´ã¿¹¾à¶õ]À¸·Î ¹®ÀÇÇϽñ⠹ٶø´Ï´Ù.
[º» ÀÇ·á »ó´ãÀº Áø·á¸¦ ´ë½Å ÇÒ ¼ö ¾ø½À´Ï´Ù.]


[RE] LTK ½Ã¼ú°ü·Ã ¹®ÀÇ ÇÕ´Ï´Ù.
±Û   ¾´   ÀÌ ¹Ù·Îº¸±â
º»         ¹® ÃÖÈĶô´ÔÀÇ ±ÛÀÔ´Ï´Ù.

:¾È³çÇϼ¼¿ä.
:
:¾Æ¹ö´Ô²²¼­ ±ÝÁÖ¿¡ ¼ö¼ú¿¹¾àÀÌ µÇ¾î ÀÖ½À´Ï´Ù.
:
:»çÀü¿¡ ¸¹Àº º» ½Ã¼ú¿¡ ¸¹Àº Áö½ÄÀÌ ¾ø´Â °ü°è·Î ±× Ÿ´ç¼ºÀ» ¼±»ý´Ô²² ÀüÀûÀ¸·Î ÀÇÁ¸ÇØ¾ß ÇÏ´Â ÀÔÀåÀÔ´Ï´Ù.
:¸¹Àº Á¡ÀÌ ±Ã±ÝÇÏ¿©, ÇØ¿Ü ¹®ÇåÀ» Á¶»çÇØ º¸´ø Áß FDA¿¡¼­ ½ÂÀÎÇÒ ´ç½Ã ÀÓ»ó°á°ú¿Í 2004³â º¸µµÀڷḦ º¸´Ï,
:Á¡Â÷ ´«ÀÌ ¿ø·¡ »óÅ·Πµ¹¾Æ°¥ È®À²ÀÌ CK, ASA80º¸´Ù ³ôÀº °ÍÀ¸·Î ³ª¿ÍÀÖ´õ±º¿ä.
:
:¾î¶² ¹æ¹ýÀ¸·Î ¼ö¼úÇϽñ⿡ ¼±»ý´Ô²²¼± "°ÅÀÇ ¹®Á¦°¡ ¹ß»ýµÇÁö ¾Ê´Â´Ù"¶ó°í ¸»¾¸Çϼ̴ÂÁö ±Ã±ÝÇÕ´Ï´Ù. ¶ÇÇÑ ´ëºÎºÐ 2³âÁ¤µµ¿¡ ½Ã·ÂÀÌ ¾ÈÁ¤È­ µÈ´Ù°í ÇÏ´øµ¥, ±× »çÀÌ¿¡ ½Ã·ÂÀÌ ¸¹ÀÌ ¿øº¹µÇ¸é ¾î¶² Á¶Ä¡¸¦ ÃëÇØ Áֽô°¡µµ ±Ã±ÝÇÕ´Ï´Ù.
:
:Á¦ ¾Æ¹ö´ÔÀÇ ¼ÒÁßÇÑ ´«À» Á¦°¡ ³ª¼­¼­ ¼ö¼úÇÏÀÚ°í ÇÏ´Â ÀÔÀåÀÌ¶ó ¼±»ý´Ô²² ¾ð¨Àº ±ÛÀ» ¿Ã¸°°Ç ¾Æ´Ñ°¡ Á˼۽º·´½À´Ï´Ù.
:
:¹Ù»Ú½Ã´õ¶óµµ Àß ¸ô¶ó ¾ÈŸ±î¿î ¸¶À½¿¡ ±ÛÀ» ¿Ã¸®¿À´Ï ȸ½Å ºÎŹµå¸³´Ï´Ù.
:
:- ÷ºÎÀÚ·á -
:
: The data analysis was based on the refractive data at all follow-up examination time points (1 month, 3, 6, 12, 18 and 24 months). At 12 months, this analysis showed that 407/409 (85.0%) eyes were corrected to 20/40 or better and 179/479 (37.4%) were corrected to 20/20 or better visual acuity without spectacles or contact lenses. 5e. The study showed that all adverse events occurred at low rates (<1%).
:
:Sunrise Corporation used a non-contact
:Holmium laser to apply a ring of spots to
:the cornea. LTK fell from favour as many
:patients had significant regression by 12
:months.
:
:Laser thermal keratoplasty (LTK).
:Sunrise¡¯s Hyperion laser system was
:approved by the FDA for the
:temporary correction of hyperopia.
:
: Long term risks of LTK for hyperopia have not been determined. The safety and effectiveness of re-treatment procedures with the HYPERION¢â LTK System or other refractive surgical devices have not been established. Limited data suggests that the reduction in refractive error following re-treatment may diminish over time.
:
:



´äº¯ÀÔ´Ï´Ù.
¾È³çÇϽʴϱî?
Ç×»ó ÃÖ¼±À» ´ÙÇÏ´Â ¹Ù·Îº¸±â ¾È°úÀÔ´Ï´Ù.
¾Æ¹ö´Ô ¼ö¼ú ¹®Á¦·Î °í¹ÎÀÌ ¸¹À¸½Å µí ÇϽñº¿ä.
¸»¾¸´ë·Î LTK´Â ¼ö¼úÈÄ Àç¹ßÀÌ µË´Ï´Ù.
±× ÀÌÀ¯´Â ¼ö¼úÀÚüÀÇ ¹®Á¦À̱⺸´Ù´Â ´«ÀÇ ³ëÈ­·Î °è¼ÓÀûÀ¸·Î ³ë¾ÈÀÌ ÁøÇàµÇ±â ¶§¹®À̸ç ÀúÈñ ¹Ù·Îº¸±â¿¡¼­ ±¹³» °³ÀÎ ¾È°ú ÃÖÃÊ·Î ½Ã¼úÀ» ½ÃÀÛÇÏ¿´°í ±× °£ ¼ö¼úÀ» °è¼ÓÇϸ鼭 ¸¹Àº ȯÀںеéÀÇ ÀÓ»ó°á°ú¸¦ º¸¸é »ó´ç¼öÀÇ È¯Àںе鿡°Ô 4~5³âÀ̳» Àç¼ö¼úÀÌ ÇÊ¿äÇÒ Á¤µµÀÇ Àç¹ßÀº °ÅÀÇ ¾ø¾úÀ¸¸ç ³ªÀÌ°¡ Àþ°í ¿ø½Ã°¡ ½ÉÇÑ °æ¿ì¿¡ Àç¹ßÀÌ ´õ »¡¶ú½À´Ï´Ù. CK´Â LTKÀÇ ¿ø¸®¸¦ µû¶ó¼­ ÇÏ´Â ¼ö¼úÀÌÁö¸¸ ³­½Ã¹ß»ý·üÀÌ ³ô°í ¼ö¼úÈÄ Àç¹ßÀÌ µÇ¾úÀ» ¶§ Àç¼ö¼úÀÌ ¾î·Á¿ì¸ç LTK´Â ºñÁ¢Ã˽ÄÀε¥ ºñÇØ CK´Â Á¢Ã˽ÄÀ̶ó´Â Á¡, ¼ö¼úÀåºñ±¸ÀÔÀÇ °æÁ¦ÀûÃø¸éµîÀÌ Â÷ÀÌÁ¡ÀÔ´Ï´Ù ASA 80Àº ¶ó¼½À̳ª ¶ó½Ä¼ö¼ú¹ýÀ¸·Î ¿ø½Ã³ë¾ÈÀ» Ä¡·áÇϴ¹ýÀ¸·Î ¿ª½Ã Àç¹ßÀ» ÇÊ¿¬À̶ó°í »ý°¢µÇ¾îÁý´Ï´Ù.
³ë¾ÈÀÇ Àç¹ßÀº ³ªÀÌ°¡ µé¼ö·Ï µ¸º¸±â µ¾¼ö°¡ ÀÏÁ¤±â°£µ¿¾È ³ô¾ÆÁö¼Å¼­ ¾È°æÀ» ¹Ù²Ù´Â °Í°ú µ¿ÀÏÇÑ ¿ø¸®¶ó°í »ý°¢ÇÏ½Ã¸é µË´Ï´Ù.
LTK´Â Àç¼ö¼úÀÌ 10ȸ°¡·® °¡´ÉÇϽʴϴÙ.
ÀúÈñ ¹Ù·Îº¸±â¿¡¼­ ¼ö¼ú¹ÞÀ¸½Å ºÐµéÀÇ ¼ö¼úÈÄ À̾߱⸦ µé¾îº¸½Ã¸é ÁÁÀ¸½Ç °Í °°½À´Ï´Ù.
´õ¿í ÀÚ¼¼ÇÑ ¹®ÀÇ´Â ÀüÈ­·Î ¶Ç Áֽʽÿä.
¿¹¾àÀÏ¿¡ ºË°Ø½À´Ï´Ù.
¸ñ·ÏÀ¸·Î